JGJeisson Gómez-Robles

Jeisson Gómez-Robles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeisson Gómez-Robles has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Venomics of the Anchor Coral Snake Micrurus ancoralis: Composition, Toxicological Profile, and Neutralization by Commercial Antivenom

    by Paola Rey-Suárez, Jonard David Echavarría-Rentería, Jeisson Gómez-Robles, Jaime Andrés Pereañez, Mónica Saldarriaga-Córdoba, Bruno Lomonte, Julián Fernández, Vitelbina Núñez

    Coral snakes of the American continent are classified into two genera, Micruroides and Micrurus, with as many as 91 species recognized in the latter. Although envenomings caused by Micrurus are rare, they can be life-threatening due to neurotoxic effects leading to flaccid paralysis and potential respiratory failure. Micrurus ancoralis is found in the Pacific lowlands and along the western slope of the cordillera occidental Cordillera in Colombia. Although this species is relatively common within its distribution range, its phylogenetic position and the characterization of its venom have not been investigated. The results of phylogenetic analysis placed M. ancoralis within the triadal/bicolor clade of species with the characteristic triad pattern and group bicolor. Proteomic characterization of the venom showed predominance of phospholipase A2 (PLA2) enzymes in its composition, with 51.7% of the total protein content, followed by three-finger toxins (3FTxs; 23.2%) and lower proportions of proteins belonging to several other minor families. Out of 28 chromatographic venom fractions obtained, the seven most abundant were evaluated for toxicity, with three of them (F7, identified as a 3FTx, and F18 and F20 (both identified as PLA2s)) showing lethal activity by the intraperitoneal route in mice. The PLA2 activity of F20 was confirmed and its edema-inducing, myotoxic, and lethal effects in mice were demonstrated. A therapeutic equine anti-coral antivenom (INS, Colombia) against coral snake envenomings immunorecognized the whole venom and its fractions in ELISA tests and was able to neutralize 2 × LD50 (medial lethal dose) of M. ancoralis venom by preincubation, with an estimated potency of at least 0.2 mg venom/mL antivenom. This result suggests that envenomings by M. ancoralis could be effectively treated by this antivenom.

  • Open Access

    Micrurus nigrocinctus in Colombia: Integrating Venomics Research, Citizen Science, and Community Empowerment

    by Paola Rey-Suárez, Lina Preciado Rojo, Jeisson Gómez-Robles, Sanin Parra-Moreno, Erica Pachon-Camelo, Yirlys Fuentes-Florez, Bruno Lomonte, Julián Fernández, Mahmood Sasa, Vitelbina Núñez, et al.

    Snakebite is a high-priority neglected tropical disease, and a strategic goal based on four pillars has been recommended to reduce mortality and morbidity. One is empowering rural communities through citizen science, education, and engagement. In this study, an integrative approach was used to expand our knowledge of Micrurus nigrocinctus status and characterize its venom. Using citizen science data and field visits to local communities, 99 records of M. nigrocinctus distributed in Antioquia, Chocó, and Córdoba were obtained. Children, young people, and adults recognized M. nigrocinctus as the most common coral snake species in their region, and two specimens were recovered for venomic and Phylogenetic analyses. The M. nigrocinctus venom from Colombia exhibited similar chromatographic and electrophoretic profiles and biological activities and shared nearly identical protein families with Costa Rica. Commercial coral snake antivenoms also recognized and neutralized the whole venom from both countries. However, phylogenetic relationships showed greater divergence with specimens from Costa Rica. Involving communities helps prevent coral snake bites and facilitates access to rare specimens such as M. nigrocinctus, thereby enabling venom analyses, improving antivenom evaluation, and advancing toxinology research for medically significant species.


  • Open Access

    Standard Quality Characteristics and Efficacy of a New Third-Generation Antivenom Developed in Colombia Covering Micrurus spp. Venoms

    by Santiago Tabares Vélez, Lina María Preciado, Leidy Johana Vargas Muñoz, Carlos Alberto Madrid Bracamonte, Angelica Zuluaga, Jeisson Gómez Robles, Camila Renjifo-Ibañez, Sebastián Estrada-Gómez

    In Colombia, Micrurus snakebites are classified as severe according to the national clinical care guidelines and must be treated with specific antivenoms. Unfortunately, these types of antivenoms are scarce in certain areas of the country and are currently reported as an unavailable vital medicine. To address this issue, La Universidad de Antioquia, through its spin-off Tech Life Saving, is leading a project to develop third-generation polyvalent freeze-dried antivenom. The goal is to ensure access to this therapy, especially in rural and dispersed areas. This project aims to evaluate the physicochemical and preclinical parameters (standard quality characteristics) of a lab-scale anti-elapid antivenom batch. The antivenom is challenged against the venoms of several Micrurus species, including M. mipartitus, M. dumerilii, M. ancoralis, M. dissoleucus, M. lemniscatus, M. medemi, M. spixii, M. surinamensis, and M. isozonus, following the standard quality characteristics set by the World Health Organization (WHO). The antivenom demonstrates an appearance consistent with standards, 100% solubility within 4 min and 25 s, an extractable volume of 10.39 mL, a pH of 6.04, an albumin concentration of 0.377 mg/mL (equivalent to 1.22% of total protein), and a protein concentration of 30.97 mg/mL. Importantly, it maintains full integrity of its F(ab′)2 fragments and exhibits purity over 98.5%. Furthermore, in mice toxicity evaluations, doses up to 15 mg/mouse show no toxic effects. The antivenom also demonstrates a significant recognition pattern against Micrurus venoms rich in phospholipase A2 (PLA2) content, as observed in M. dumerilii, M. dissoleucus, and M. isozonus. The effective dose 50 (ED50) indicates that a single vial (10 mL) can neutralize 2.33 mg of M. mipartitus venom and 3.99 mg of M. dumerilii venom. This new anti-elapid third-generation polyvalent and freeze-dried antivenom meets the physicochemical parameters set by the WHO and the regulators in Colombia. It demonstrates significant efficacy in neutralizing the venom of the most epidemiologically important Micrurus species in Colombia. Additionally, it recognizes seven other species of Micrurus venom with a higher affinity for venoms exhibiting PLA2 toxins. Fulfilling these parameters represents the first step toward proposing a new pharmacological alternative for treating snakebites in Colombia, particularly in dispersed rural areas, given that this antivenom is formulated as a freeze-dried product.